English

TITAN PHARMACEUTICALS INC

EDGAR

TTNP Quarterly report (10-Q) · filed 2025-08-14

138 filing records in this dataset, filed from 1996-05-15 to 2025-08-14. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

1.22 million Unit12

2019 Q4 · Unit12

Exact inputs and evidence

Revenue: 1217000 Unit12 Source

Operating margin

425.14%

2019 Q4 · %

Exact inputs and evidence

Operating Income: -7876000 Unit12 Source
Operating Income: -13050000 Unit12 Source
Revenue: 1217000 Unit12 Source

Operating cash flow

-3.66 million Unit12

2019 Q4 · Unit12

Exact inputs and evidence

Operating Cash Flow: -15445000 Unit12 Source
Operating Cash Flow: -11782000 Unit12 Source

Free cash flow

-3.78 million Unit12

2019 Q4 · Unit12

Exact inputs and evidence

Operating Cash Flow: -15445000 Unit12 Source
Operating Cash Flow: -11782000 Unit12 Source
Capital Expenditure: 256000 Unit12 Source
Capital Expenditure: 144000 Unit12 Source

Cash and cash equivalents: 2.8 million USD 2025-06-30 Source
Exact value

2803000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 1.33 million shares 2025-06-30 Source
Exact value

1330234 shares

Reported share-count change

45.50% · 416 thousand shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

914234 shares · 2024-06-30· Source
1330234 shares · 2025-06-30· Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2025-08-14.

Financial data available through: 2024-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2018-12-31
Operating income: 9 of 11 periods available· newest 2024-12-31
Net income: 9 of 11 periods available· newest 2024-12-31
Operating cash flow: 9 of 11 periods available· newest 2024-12-31
Capital expenditure: 7 of 11 periods available· newest 2023-12-31
Total assets: 9 of 11 periods available· newest 2024-12-31
Total liabilities: 9 of 11 periods available· newest 2024-12-31
Current assets: 9 of 11 periods available· newest 2024-12-31
Current liabilities: 9 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 9 of 11 periods available· newest 2024-12-31
long term debt: No compatible figures in this window
Shares outstanding: 9 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
+USD 863,000

Prior period

−USD 5.57 million

2023-01-01 – 2023-12-31
Current period

−USD 4.71 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-4706000 − -5569000 = 863000 USD

-5569000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-4706000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TITAN PHARMACEUTICALS INC · 2024-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Year-over-year change in Net income: 863000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -4706000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#790389 Filing: 000182912625001934 Input fundies:NetIncome: -5569000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#774945 Filing: 000182912625001934
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 3.21 million

Prior period

−USD 7.09 million

2023-01-01 – 2023-12-31
Current period

−USD 3.88 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-3880000 − -7092000 = 3212000 USD

-7092000 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-3880000 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TITAN PHARMACEUTICALS INC · 2024-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Year-over-year change in Operating cash flow: 3212000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -3880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#817737 Filing: 000182912625001934 Input fundies:OperatingCashFlow: -7092000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#818222 Filing: 000182912625001934
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue, Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2018-01-01 – 2018-12-31

Revenue USD 6.62 million 100% of revenue
Operating costs Derived USD 14.88 million 225% of revenue
Operating income −USD 8.26 million −125% of revenue
Tax, interest and other Derived USD 759,000 11% of revenue
Net income −USD 9.02 million −136% of revenue

Cash

Operating cash flow −USD 8.43 million −127% of revenue
Capital expenditure USD 416,000 6.3% of revenue
Free cash flow Derived −USD 8.85 million −134% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2014 Operating loss: operating costs were 195% of revenue.
2015 Operating loss: operating costs were 504% of revenue.
2016 Net income was higher than operating income, so the split is not drawn.
2017 Operating loss: operating costs were 6,845% of revenue.
2018 Operating loss: operating costs were 225% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2014 2014-01-01 – 2014-12-31	3646000	7121000 Derived	-3475000	-1072000 Derived	-2403000	-5883000 Derived	Source 2014-01-01 – 2014-12-31: 3646000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -3475000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -2403000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -5865000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 18000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	1671000	8430000 Derived	-6759000	4520000 Derived	-11279000	-7599000 Derived	Source 2015-01-01 – 2015-12-31: 1671000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -6759000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -11279000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -7466000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 133000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	15065000	10722000 Derived	4343000	-792000 Derived	5135000	6122000 Derived	Source 2016-01-01 – 2016-12-31: 15065000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: 4343000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: 5135000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 6293000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 171000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	215000	14717000 Derived	-14502000	-195000 Derived	-14307000	-12852000 Derived	Source 2017-01-01 – 2017-12-31: 215000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -14502000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -14307000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -12677000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 175000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	6618000	14882000 Derived	-8264000	759000 Derived	-9023000	-8847000 Derived	Source 2018-01-01 – 2018-12-31: 6618000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -8264000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -9023000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -8431000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 416000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 6.6M 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Revenue	3646000	Revenue: 3646000 Open source
20152015-12-31	Revenue	1671000	Revenue: 1671000 Open source
20162016-12-31	Revenue	15065000	Revenue: 15065000 Open source
20172017-12-31	Revenue	215000	Revenue: 215000 Open source
20182018-12-31	Revenue	6618000	Revenue: 6618000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

2,978.1% 2018

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Year over year	No prior comparable period	Revenue: 3646000 Open source
20152015-12-31	Year over year	-54.2%	Revenue: 1671000 Open source Revenue: 3646000 Open source
20162016-12-31	Year over year	801.6%	Revenue: 15065000 Open source Revenue: 1671000 Open source
20172017-12-31	Year over year	-98.6%	Revenue: 215000 Open source Revenue: 15065000 Open source
20182018-12-31	Year over year	2,978.1%	Revenue: 6618000 Open source Revenue: 215000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -124.9% 2018

Net margin -136.3% 2018

Free cash flow margin -133.7% 2018

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Operating margin	-95.3%	Operating Income: -3475000 Open source Revenue: 3646000 Open source
20152015-12-31	Operating margin	-404.5%	Operating Income: -6759000 Open source Revenue: 1671000 Open source
20162016-12-31	Operating margin	28.8%	Operating Income: 4343000 Open source Revenue: 15065000 Open source
20172017-12-31	Operating margin	-6,745.1%	Operating Income: -14502000 Open source Revenue: 215000 Open source
20182018-12-31	Operating margin	-124.9%	Operating Income: -8264000 Open source Revenue: 6618000 Open source
20142014-12-31	Net margin	-65.9%	Net Income: -2403000 Open source Revenue: 3646000 Open source
20152015-12-31	Net margin	-675%	Net Income: -11279000 Open source Revenue: 1671000 Open source
20162016-12-31	Net margin	34.1%	Net Income: 5135000 Open source Revenue: 15065000 Open source
20172017-12-31	Net margin	-6,654.4%	Net Income: -14307000 Open source Revenue: 215000 Open source
20182018-12-31	Net margin	-136.3%	Net Income: -9023000 Open source Revenue: 6618000 Open source
20142014-12-31	Free cash flow margin	-161.4%	Revenue: 3646000 Open source Operating Cash Flow: -5865000 Open source Capital Expenditure: 18000 Open source
20152015-12-31	Free cash flow margin	-454.8%	Revenue: 1671000 Open source Operating Cash Flow: -7466000 Open source Capital Expenditure: 133000 Open source
20162016-12-31	Free cash flow margin	40.6%	Revenue: 15065000 Open source Operating Cash Flow: 6293000 Open source Capital Expenditure: 171000 Open source
20172017-12-31	Free cash flow margin	-5,977.7%	Revenue: 215000 Open source Operating Cash Flow: -12677000 Open source Capital Expenditure: 175000 Open source
20182018-12-31	Free cash flow margin	-133.7%	Revenue: 6618000 Open source Operating Cash Flow: -8431000 Open source Capital Expenditure: 416000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -8.4M 2018

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Operating cash flow	-5865000	Operating Cash Flow: -5865000 Open source
20152015-12-31	Operating cash flow	-7466000	Operating Cash Flow: -7466000 Open source
20162016-12-31	Operating cash flow	6293000	Operating Cash Flow: 6293000 Open source
20172017-12-31	Operating cash flow	-12677000	Operating Cash Flow: -12677000 Open source
20182018-12-31	Operating cash flow	-8431000	Operating Cash Flow: -8431000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -8.8M 2018

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20142014-12-31	Free cash flow	-5883000	Operating Cash Flow: -5865000 Open source Capital Expenditure: 18000 Open source
20152015-12-31	Free cash flow	-7599000	Operating Cash Flow: -7466000 Open source Capital Expenditure: 133000 Open source
20162016-12-31	Free cash flow	6122000	Operating Cash Flow: 6293000 Open source Capital Expenditure: 171000 Open source
20172017-12-31	Free cash flow	-12852000	Operating Cash Flow: -12677000 Open source Capital Expenditure: 175000 Open source
20182018-12-31	Free cash flow	-8847000	Operating Cash Flow: -8431000 Open source Capital Expenditure: 416000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

51.5% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Liabilities / assets	58.7%	Total Liabilities: 12240000 Open source Total Assets: 20851000 Open source
20152015-12-31	Liabilities / assets	47.4%	Total Liabilities: 6297000 Open source Total Assets: 13287000 Open source
20162016-12-31	Liabilities / assets	29.3%	Total Liabilities: 5476000 Open source Total Assets: 18667000 Open source
20172017-12-31	Liabilities / assets	90.4%	Total Liabilities: 8048000 Open source Total Assets: 8905000 Open source
20182018-12-31	Liabilities / assets	51.5%	Total Liabilities: 7264000 Open source Total Assets: 14095000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

3.85× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20142014-12-31	Current assets / current liabilities	2.94×	Current Assets: 19583000 Open source Current Liabilities: 6662000 Open source
20152015-12-31	Current assets / current liabilities	2.52×	Current Assets: 12244000 Open source Current Liabilities: 4853000 Open source
20162016-12-31	Current assets / current liabilities	3.67×	Current Assets: 17830000 Open source Current Liabilities: 4857000 Open source
20172017-12-31	Current assets / current liabilities	1.86×	Current Assets: 8310000 Open source Current Liabilities: 4464000 Open source
20182018-12-31	Current assets / current liabilities	3.85×	Current Assets: 13301000 Open source Current Liabilities: 3452000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2014 2014-01-01 – 2014-12-31	−USD 2.4 million Exact value Exact value: -2403000 USD 2014-01-01 – 2014-12-31: -2403000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2014-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: -2403000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2403000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420417014986/ttnp-20161231.xml#97849 Filing: 000114420417014986 The citation records this snapshot. The page link may show a newer release later.	−USD 5.87 million Exact value Exact value: -5865000 USD 2014-01-01 – 2014-12-31: -5865000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2014-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: -5865000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -5865000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420417014986/ttnp-20161231.xml#116804 Filing: 000114420417014986 The citation records this snapshot. The page link may show a newer release later.	USD 18,000 Exact value Exact value: 18000 USD 2014-01-01 – 2014-12-31: 18000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TITAN PHARMACEUTICALS INC · 2014-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Capital Expenditure: 18000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 18000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420417014986/ttnp-20161231.xml#117042 Filing: 000114420417014986 The citation records this snapshot. The page link may show a newer release later.	−USD 5.88 million Calculation and evidence -5865000 − 18000 USD Exact free cash flow: -5883000 USD 2014-01-01 – 2014-12-31: -5865000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 18000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TITAN PHARMACEUTICALS INC · 2014-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Free cash flow: -5883000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5865000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420417014986/ttnp-20161231.xml#116804 Filing: 000114420417014986 Input fundies:CapitalExpenditure: 18000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420417014986/ttnp-20161231.xml#117042 Filing: 000114420417014986 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 11.28 million Exact value Exact value: -11279000 USD 2015-01-01 – 2015-12-31: -11279000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2015-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: -11279000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11279000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420418018448/ttnp-20171231.xml#115882 Filing: 000114420418018448 The citation records this snapshot. The page link may show a newer release later.	−USD 7.47 million Exact value Exact value: -7466000 USD 2015-01-01 – 2015-12-31: -7466000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2015-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: -7466000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7466000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420418018448/ttnp-20171231.xml#127161 Filing: 000114420418018448 The citation records this snapshot. The page link may show a newer release later.	USD 133,000 Exact value Exact value: 133000 USD 2015-01-01 – 2015-12-31: 133000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TITAN PHARMACEUTICALS INC · 2015-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Capital Expenditure: 133000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 133000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420418018448/ttnp-20171231.xml#127359 Filing: 000114420418018448 The citation records this snapshot. The page link may show a newer release later.	−USD 7.6 million Calculation and evidence -7466000 − 133000 USD Exact free cash flow: -7599000 USD 2015-01-01 – 2015-12-31: -7466000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 133000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TITAN PHARMACEUTICALS INC · 2015-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Free cash flow: -7599000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7466000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420418018448/ttnp-20171231.xml#127161 Filing: 000114420418018448 Input fundies:CapitalExpenditure: 133000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420418018448/ttnp-20171231.xml#127359 Filing: 000114420418018448 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	USD 5.14 million Exact value Exact value: 5135000 USD 2016-01-01 – 2016-12-31: 5135000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2016-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: 5135000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: 5135000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2958240 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	USD 6.29 million Exact value Exact value: 6293000 USD 2016-01-01 – 2016-12-31: 6293000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2016-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: 6293000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 6293000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332432 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	USD 171,000 Exact value Exact value: 171000 USD 2016-01-01 – 2016-12-31: 171000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TITAN PHARMACEUTICALS INC · 2016-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Capital Expenditure: 171000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 171000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2333039 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	USD 6.12 million Calculation and evidence 6293000 − 171000 USD Exact free cash flow: 6122000 USD 2016-01-01 – 2016-12-31: 6293000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 171000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TITAN PHARMACEUTICALS INC · 2016-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Free cash flow: 6122000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 6293000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332432 Filing: 000114420419017559 Input fundies:CapitalExpenditure: 171000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2333039 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 14.31 million Exact value Exact value: -14307000 USD 2017-01-01 – 2017-12-31: -14307000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2017-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: -14307000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14307000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2958093 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	−USD 12.68 million Exact value Exact value: -12677000 USD 2017-01-01 – 2017-12-31: -12677000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2017-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: -12677000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -12677000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332227 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	USD 175,000 Exact value Exact value: 175000 USD 2017-01-01 – 2017-12-31: 175000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TITAN PHARMACEUTICALS INC · 2017-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Capital Expenditure: 175000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 175000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332837 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	−USD 12.85 million Calculation and evidence -12677000 − 175000 USD Exact free cash flow: -12852000 USD 2017-01-01 – 2017-12-31: -12677000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 175000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TITAN PHARMACEUTICALS INC · 2017-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Free cash flow: -12852000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -12677000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332227 Filing: 000114420419017559 Input fundies:CapitalExpenditure: 175000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332837 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 9.02 million Exact value Exact value: -9023000 USD 2018-01-01 – 2018-12-31: -9023000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2018-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: -9023000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -9023000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2957947 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	−USD 8.43 million Exact value Exact value: -8431000 USD 2018-01-01 – 2018-12-31: -8431000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2018-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: -8431000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8431000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332023 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	USD 416,000 Exact value Exact value: 416000 USD 2018-01-01 – 2018-12-31: 416000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TITAN PHARMACEUTICALS INC · 2018-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Capital Expenditure: 416000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 416000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332635 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.	−USD 8.85 million Calculation and evidence -8431000 − 416000 USD Exact free cash flow: -8847000 USD 2018-01-01 – 2018-12-31: -8431000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 416000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TITAN PHARMACEUTICALS INC · 2018-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Free cash flow: -8847000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -8431000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332023 Filing: 000114420419017559 Input fundies:CapitalExpenditure: 416000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000114420419017559/ttnp-20181231.xml#2332635 Filing: 000114420419017559 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 8.78 million Exact value Exact value: -8776000 USD 2021-01-01 – 2021-12-31: -8776000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2021-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: -8776000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -8776000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912623002504/titanpharma_10k.htm#727088 Filing: 000182912623002504 The citation records this snapshot. The page link may show a newer release later.	−USD 7.9 million Exact value Exact value: -7899000 USD 2021-01-01 – 2021-12-31: -7899000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2021-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: -7899000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7899000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912623002504/titanpharma_10k.htm#790055 Filing: 000182912623002504 The citation records this snapshot. The page link may show a newer release later.	USD 23,000 Exact value Exact value: 23000 USD 2021-01-01 – 2021-12-31: 23000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TITAN PHARMACEUTICALS INC · 2021-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Capital Expenditure: 23000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 23000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912623002504/titanpharma_10k.htm#792295 Filing: 000182912623002504 The citation records this snapshot. The page link may show a newer release later.	−USD 7.92 million Calculation and evidence -7899000 − 23000 USD Exact free cash flow: -7922000 USD 2021-01-01 – 2021-12-31: -7899000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 23000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TITAN PHARMACEUTICALS INC · 2021-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Free cash flow: -7922000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7899000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912623002504/titanpharma_10k.htm#790055 Filing: 000182912623002504 Input fundies:CapitalExpenditure: 23000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912623002504/titanpharma_10k.htm#792295 Filing: 000182912623002504 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 10.21 million Exact value Exact value: -10206000 USD 2022-01-01 – 2022-12-31: -10206000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2022-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: -10206000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -10206000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912624002110/titanpharma_10k.htm#730968 Filing: 000182912624002110 The citation records this snapshot. The page link may show a newer release later.	−USD 8.18 million Exact value Exact value: -8183000 USD 2022-01-01 – 2022-12-31: -8183000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2022-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: -8183000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -8183000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912624002110/titanpharma_10k.htm#779766 Filing: 000182912624002110 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2023 2023-01-01 – 2023-12-31	−USD 5.57 million Exact value Exact value: -5569000 USD 2023-01-01 – 2023-12-31: -5569000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2023-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: -5569000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5569000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#774945 Filing: 000182912625001934 The citation records this snapshot. The page link may show a newer release later.	−USD 7.09 million Exact value Exact value: -7092000 USD 2023-01-01 – 2023-12-31: -7092000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2023-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: -7092000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -7092000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#818222 Filing: 000182912625001934 The citation records this snapshot. The page link may show a newer release later.	USD 2,000 Exact value Exact value: 2000 USD 2023-01-01 – 2023-12-31: 2000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TITAN PHARMACEUTICALS INC · 2023-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Capital Expenditure: 2000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#821310 Filing: 000182912625001934 The citation records this snapshot. The page link may show a newer release later.	−USD 7.09 million Calculation and evidence -7092000 − 2000 USD Exact free cash flow: -7094000 USD 2023-01-01 – 2023-12-31: -7092000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 2000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TITAN PHARMACEUTICALS INC · 2023-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Free cash flow: -7094000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7092000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#818222 Filing: 000182912625001934 Input fundies:CapitalExpenditure: 2000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#821310 Filing: 000182912625001934 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 4.71 million Exact value Exact value: -4706000 USD 2024-01-01 – 2024-12-31: -4706000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TITAN PHARMACEUTICALS INC · 2024-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Net Income: -4706000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4706000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#790389 Filing: 000182912625001934 The citation records this snapshot. The page link may show a newer release later.	−USD 3.88 million Exact value Exact value: -3880000 USD 2024-01-01 – 2024-12-31: -3880000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TITAN PHARMACEUTICALS INC · 2024-12-31 TITAN PHARMACEUTICALS INC (edgar:910267) Operating Cash Flow: -3880000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T09:13:56Z Snapshot: 0177ecff99dc0cc5f3067168758b5dc5e4aa8f7b41a7d7bf09acd32f36bff79f Dimensions: Consolidated View: https://fundies.io/companies/edgar/910267/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -3880000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/910267/000182912625001934/titanpharma_10k.htm#817737 Filing: 000182912625001934 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

138 filings · 4,253 latest values · 4,253 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000910267, 910267, TTNP, edgar:910267

Also known as TITAN PHARMACEUTICALS INC, TITAN PHARMACEUTICALS, INC., TITAN PHARMACEUTICALS, INC., Titan Pharmaceuticals, Inc., Titan Pharmaceuticals, Inc.

TITAN PHARMACEUTICALS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Company performance

What changed year over year

Net income

Operating cash flow

Where revenue goes

2018 2018-01-01 – 2018-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation